Skip to main content

Table 1 Patient characteristics

From: Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis

Characteristics NSCLC
n = 96
n, (%)
HNC/GC
n = 92
n, (%)
P-value
Age, years
 Median (range) 68 (44–80) 67 (24–85) 0.46
  < 65 33 (34.4) 38 (41.3)  
  ≥ 65 63 (65.6) 54 (58.7)  
Sex 0.98
 Male 68 (70.8) 65 (70.7)  
 Female 28 (29.2) 27 (29.3)  
Smoking status 0.40
 Current/ex-smoker 75 (78.1) 67 (72.8)  
 Current smoker 5 (5.2) 11 (12.0)  
 Ex-smoker 70 (72.9) 56 (60.9)  
  < 20 pack-years 12 (12.5) 18 (19.6)  
  ≥ 20 pack-years 63 (65.6) 45 (48.9)  
 Unknown pack-years 0 4 (4.3)  
 Never-smoker 21 (21.9) 25 (27.2)  
Performance status 0.36
 0–1 82 (85.4) 74 (80.4)  
  ≥ 2 14 (14.6) 18 (19.6)  
Prevalence of patient comorbidities
 Arterial hypertension 30 (31.3) 26 (28.3) 0.65
 Cardiovascular disease 5 (5.2) 8 (8.7) 0.35
 Diabetes 11 (11.5) 12 (13.0) 0.74
 COPD 12 (12.5) 3 (3.3) 0.029a
No. of treatment cycles of nivolumab
 Median (range) 5 (1–58) 5 (1–25) 0.42
 Pre-existing ILD on chest CT
 Normal 70 (72.9) 78 (84.8) 0.047
 Pre-existing ILD 26 (27.1) 14 (15.2)  
 UIP 6 (6.3) 2 (2.2)  
 Possible UIP 3 (3.1) 1 (1.1)  
 Inconsistent with UIP 17 (17.7) 11 (12.0)  
  1. NSCLC non-small cell lung cancer, HNC head and neck cancer, GC gastric cancer, COPD chronic obstructive pulmonary disease, ILD interstitial lung disease, CT computed tomography, UIP usual interstitial pneumonia, a Fisher’s exact test